Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with ...

A Central Illinois cardiologist breaks down the potential benefits of GLP-1 medications on heart health. It was one of the ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

as well as an oral peptide delivery technology, according to Evercore ISI analysts. Ciara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist). It is a peptide or, in other words, a very short protein. This is the active ingredient in Ozempic, Wegovy ...

Glucagon-like peptide 1 (GLP-1), for example, is a peptide secreted by the gastrointestinal tract in response to food intake, which leads to the secretion of insulin and inhibition of glucagon ...

I will be particularly interested in the company’s plan to attract and retain weight loss subscribers in the coming absence of popular GLP-1 compounds.

Relative effects of genetically proxied glucagon‐like peptide‐1 receptor agonism on muscle and fat mass: A Mendelian randomization study. Diabetes, Obesity and Metabolism , 2025; DOI: 10.1111 ...

Image credit: James Manning – PA Images/Getty Images. Glucagon-like peptide-1 receptor agonists (GLP-1) drugs are a class of medications used to manage type 2 diabetes and treat obesity.

The growing popularity of GLP-1 agonists for weight management has sparked a surge in alternative dosing methods, particularly microdosing of Ozempic. This emerging practice involves intentionally ...